Page 4 of 8 – SEC Filing
| CUSIP No. 86627R102 | 13D/A |
Statement on Schedule 13D/A
| ITEM 1. | SECURITY AND ISSUER. |
This statement on Schedule
13D/A (the “Schedule 13D/A“) relates to the Ordinary Shares, par value £0.01 per share (the “Ordinary
Shares“) and the American Depositary Shares, each representing five Ordinary Shares (the “ADSs” and
together with the Ordinary Shares, the “Shares”), of Summit Therapeutics PLC, a foreign private issuer incorporated
in England and Wales whose principal executive office is located at 136A Eastern Avenue, Milton Park, Abingdon, Oxfordshire OX14
4SB, United Kingdom (the “Issuer“).
| ITEM 2. | IDENTITY AND BACKGROUND. |
(a-c, f) This Schedule
13D/A is being filed on behalf of: (i) Lansdowne Partners (UK) LLP, an English limited liability partnership (“Lansdowne“)
and (ii) Lansdowne Developed Markets Master Fund Limited, a Cayman Islands exempted company (the “Fund” and together
with Lansdowne, the “Reporting Persons”). The Fund is a privately offered investment fund that holds the Shares
reported in this Schedule 13D/A. Lansdowne is the investment adviser to the Fund and as a result is the beneficial owner of the
Shares reported in this Schedule 13D/A.
The principal business address of Lansdowne
is 15 Davies Street, London W1K 3AG, England and the principal business address of the Fund is c/o BNP Paribas Fund Administration
Services, 2 Grand Canal Plaza, Grand Canal Street, Dublin 2, Ireland.
(d) None
of the Reporting Persons, individually or collectively, has, during the last five years, been convicted in a criminal proceeding
(excluding traffic violations or similar misdemeanors).
(e) None
of the Reporting Persons has, during the last five years, been a party to a civil proceeding of a judicial or administrative body
of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future
violations of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with
respect to such laws.
| ITEM 3. | SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION. |
The funds for the purchase
of the Shares beneficially owned by the Reporting Persons came from the working capital of the Fund. The total cost for the Ordinary
Shares beneficially owned by the Reporting Persons is £18,676,103 and the total cost for the ADSs beneficially owned by the
Reporting Persons is $17,373,659. No borrowed funds were used to purchase the Shares, other than any borrowed funds used for working
capital purposes (including certain leverage arrangements) in the ordinary course of business.
| ITEM 4. | PURPOSE OF TRANSACTION. |
The Reporting Persons hold
the securities described in Item 5 of this statement for investment purposes only.
The Reporting Persons have
no plan or proposal which relates to, or would result in, any of the actions enumerated in Item 4 of the instructions to Schedule
13D/A.
